乌帕替尼治疗特应性皮炎6年随机临床试验安全性分析
基于三项全球3期试验(MeasureUp 1/2和ADUp)的6年安全性数据,纳入12-75岁接受乌帕替尼15mg或30mg至少一剂的患者共2683例。严重不良事件率两组相似,大多数特殊关注不良事件率相似,但带状疱疹、肝病、中性粒细胞减少和CPK升高呈剂量依赖性。未发现新的重要安全性信号。
要点
- 乌帕替尼15mg与30mg严重不良事件率相似(6.6 vs 7.4事件/100患者年)。
- 带状疱疹、肝病、中性粒细胞减少和CPK升高呈剂量依赖性。
- adjudicated主要不良心血管事件和静脉血栓栓塞事件发生率极低。
核心结论
- 乌帕替尼治疗中度至重度特应性皮炎长达6年未发现新的重要安全性信号。
研究设计与样本
- 分析三项全球3期研究(MeasureUp 1、MeasureUp 2和ADUp)的安全性数据。
- 纳入12-75岁接受至少1剂乌帕替尼15mg或30mg的青少年和成人患者共2683例,随访6年。
主要发现
- 严重不良事件率:乌帕替尼15mg为6.6事件/100患者年,30mg为7.4事件/100患者年。
- 鼻咽炎最常见(15mg:9.8事件/100患者年;30mg:9.3事件/100患者年),排除COVID-19。
- 严重感染率相似:15mg为2.2事件/100患者年,30mg为2.6事件/100患者年。
- 大多数特殊关注不良事件率相似,但带状疱疹、肝病、中性粒细胞减少和CPK升高呈剂量依赖性。
- 裁决的主要不良心血管事件发生率:15mg为0.2事件/100患者年,30mg为<0.1事件/100患者年;静脉血栓栓塞事件均为0.1事件/100患者年。
临床怎么用
- 长期使用乌帕替尼需关注剂量依赖性不良事件,如带状疱疹、肝病、中性粒细胞减少和CPK升高。
- 严重感染、心血管事件和恶性肿瘤发生率低,但仍需在治疗中监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease characterized by eczematous lesions, dry skin and intense pruritus. Upadacitinib, a selective JAK1 inhibitor approved for moderate-to-severe AD in adults and adolescents, is a once-daily oral treatment. OBJECTIVES: To evaluate the long-term safety profile of the treatment of moderate-to-severe AD with upadacitinib 15 mg (UPA15) or 30 mg (UPA30) across 6 years. METHODS: Safety data for adverse events (AEs), including treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs) from three global phase 3 studies (MeasureUp 1, MeasureUp 2 and ADUp), were analysed. Data were included for all adolescent and adult patients (12-75 years) receiving at least 1 dose of UPA15 or UPA30 across 6 years. RESULTS: Serious adverse event rates were similar for UPA15 (6.6 events [E] per 100 patient-years [PY]) and UPA30 (7.4 E/100 PY). Nasopharyngitis was the most frequently reported adverse event (UPA15, 9.8 E/100 PY; UPA30, 9.3 E/100 PY) excluding COVID-19. Event rates for serious infections were similar for both groups (UPA15, 2.2 E/100PY; UPA30, 2.6 E/100 PY). Rates of most AESIs were similar between UPA15 and UPA30, except for those known to be dose dependent: herpes zoster, hepatic disorder, neutropenia and CPK elevation. Adjudicated major adverse cardiovascular event incidence rates were 0.2 n/100PY and <0.1 n/100PY for UPA15 and UPA30, respectively. Adjudicated venous thromboembolic event incidence rates were 0.1 n/100PY for both UPA15 and UPA30. Rates of malignancy excluding non-melanoma skin cancer were 0.3 n/100PY for UPA15 and 0.5 n/100PY for UPA30. Rates of lymphoma were <0.1 n/100PY for both groups. Rates of TEAEs leading to death were low (<0.1 E/100PYs and 0.1 E/100 PYs for UPA15 and UPA30, respectively). CONCLUSIONS: This analysis provides information about the long-term safety of upadacitinib in AD, with no new important safety signals identified for up to 6 years. Atopic dermatitis, or eczema, is a common skin condition that causes itchiness, redness, and dry skin. People can develop eczema at any age, and it can make daily life difficult for those who develop moderate or severe cases of eczema. There are different treatments for eczema, including a pill that is taken daily called upadacitinib, or UPA. This study looked at the safety of taking UPA long‐term for up to 6 years. There were 2683 patients from around the world who were between 12 and 75 years old who were included. It looked at many different safety concerns, including serious infections, cancer, and cardiovascular problems like heart attacks or strokes. The results found that the rates of having cardiovascular problems or cancer were very low for people taking UPA. The most common thing people reported while being a part of the study was common cold symptoms.
引用
- Bunick CG, Irvine AD, Silverberg JI, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. J Eur Acad Dermatol Venereol. 2025. PMID: 41239921. doi:10.1111/jdv.70172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。